• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Clinical evaluation of nafamstat mesilate (FUT 175). A new anticoagulant for plasmapheresis.

作者信息

Hosokawa S, Oyamaguchi A, Yoshida O

机构信息

Utano National Hospital, Kyoto, Japan.

出版信息

ASAIO J. 1992 Jan-Mar;38(1):59-60. doi: 10.1097/00002480-199201000-00014.

DOI:10.1097/00002480-199201000-00014
PMID:1554918
Abstract

Nafamstat mesilate (FUT), a new anticoagulant with a short half-life of biologic activity, was used in six patients who had a history of bleeding (two from the eye, two nasally, and two orally) during plasmapheresis (PP) due to overdosage of heparin. FUT (1.2 mg/kg/hr) was injected into the arterial blood line during PP. Prothrombin time (PT), activated partial thromboplastin time (APTT), bleeding time (BT), and complete blood count (CBC) were measured before and after PP. Values of PT (17 +/- 1.4 sec) after treatment were nearly 1.5 times the levels of PT (12.5 +/- 0.8 sec) before treatment. Levels of APTT after PP (70.4 +/- 4.1 sec) were nearly double the values of APTT before PP (36.8 +/- 2.6 sec). There were no significant differences between red blood cell (RBC), hemoglobin (Hgb), or platelet counts before and after PP. No patient developed thrombosis, hemorrhage, or other side effect during PP. In conclusion, the optimal dosage of FUT was 1.2 mg/kg body weight/hr during PP. FUT is recommended as a useful anticoagulant during PP treatment of patients with an increased risk of bleeding.

摘要

相似文献

1
Clinical evaluation of nafamstat mesilate (FUT 175). A new anticoagulant for plasmapheresis.
ASAIO J. 1992 Jan-Mar;38(1):59-60. doi: 10.1097/00002480-199201000-00014.
2
Application of a new anticoagulant (Nafamostat Mesilate) to control hemorrhagic complications during extracorporeal membrane oxygenation--a preliminary report.
J Pediatr Surg. 1997 Apr;32(4):531-5. doi: 10.1016/s0022-3468(97)90701-6.
3
[The effects of FUT-175 (nafamostat mesilate) on blood coagulation and experimental disseminated intravascular coagulation (DIC)].[FUT-175(甲磺酸萘莫司他)对血液凝固及实验性弥散性血管内凝血(DIC)的影响]
Nihon Yakurigaku Zasshi. 1987 Dec;90(6):313-20. doi: 10.1254/fpj.90.313.
4
Anticoagulation with nafamostat mesilate, a synthetic protease inhibitor, in hemodialysis patients with a bleeding risk.
Haemostasis. 1993 May-Jun;23(3):135-41. doi: 10.1159/000216866.
5
Plasma collection using nafamostat mesilate and dipyridamole as an anticoagulant.使用甲磺酸萘莫司他和双嘧达莫作为抗凝剂进行血浆采集。
Int J Artif Organs. 1988 May;11(3):212-6.
6
[Beneficial characteristics of protease inhibitor as an anticoagulant for extracorporeal circulation].
Rinsho Ketsueki. 1990 Jun;31(6):782-6.
7
[Effectiveness of FUT-175, protease inhibitor, as an anticoagulant to hemodialysis].
Hinyokika Kiyo. 1988 Jun;34(6):1077-81.
8
Comparative clinical trial of regional anticoagulation for hemodialysis.
ASAIO Trans. 1988 Jul-Sep;34(3):176-8.
9
Nafamostat mesilate reduces blood loss during open heart surgery.
Circulation. 1993 Nov;88(5 Pt 2):II432-6.
10
[Pharmacological studies of FUT-175, nafamstat mesilate. IV. Effects on coagulation, platelets and fibrinolysis].
Nihon Yakurigaku Zasshi. 1984 Nov;84(5):417-28.

引用本文的文献

1
Serpin family proteins as potential biomarkers and therapeutic drugs in stroke: A systematic review and meta-analysis on clinical/preclinical studies.丝氨酸蛋白酶抑制剂家族蛋白作为脑卒中的潜在生物标志物和治疗药物:临床/临床前研究的系统评价和荟萃分析。
CNS Neurosci Ther. 2023 Jul;29(7):1738-1749. doi: 10.1111/cns.14205. Epub 2023 Apr 5.
2
Spontaneous retroperitoneal bleeding: a case series.自发性腹膜后出血:病例系列
BMC Res Notes. 2014 Sep 18;7:659. doi: 10.1186/1756-0500-7-659.